Dr Alexander Mathioudakis: key facts
- Kind of voice
- Academic
- Role
- Chair of the European Respiratory Society's Group on Airway Pharmacology and Treatment and Senior Lecturer in Respiratory Medicine at the University of Manchester, UK
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 2
- Most recently quoted
- 29 Sept 2026
“This is one of the largest real-world studies to investigate GLP-1 receptor agonists and airways disease, and one of the first to examine whether effects differ between individual GLP-1 receptor agonists. It highlights the need to consider metabolic health as part of respiratory care.”
What Dr Alexander Mathioudakis has said
“The findings also support the case for including respiratory outcomes, such as asthma attacks and COPD exacerbations, in future trials of metabolic therapies.”
Chair of the European Respiratory Society's group on airway pharmacology and treatment · Respiratory (asthma/COPD) · 29 Sept 2026 · Semaglutide linked to 40% reduction in asthma attacks ↗
Where Dr Alexander Mathioudakis has been quoted
- Ozempic and Wegovy linked to nearly 40% fewer asthma attackssciencedaily.com · 29 Sept 2026
- Semaglutide linked to 40% reduction in asthma attacksthepharmacist.co.uk · 29 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.